Aduro Biotech announces preclinical data from studies with ADU-1604
Aduro Biotech announced data from preclinical studies with ADU-1604, the company's humanized anti-CTLA-4 monoclonal antibody. Data from these in vitro and in vivo studies demonstrate the potency of ADU-1604 and its ability to inhibit tumor growth and enhance T cell-dependent antibody responses. These data, which will be highlighted later today in a poster presentation at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer, underscore the potential application of ADU-1604 for the treatment of multiple cancer types, either as monotherapy or in combination with other therapies. "These data from preclinical studies of ADU-1604, a novel anti-CTLA-4 product candidate derived from our proprietary B-select antibody platform, are encouraging and provide support to file an Investigational New Drug Application to advance ADU-1604 into clinical studies," stated Andrea van Elsas, Ph.D., chief scientific officer of Aduro Biotech. "As a company with multiple programs and proprietary technology platforms, we are well positioned to leverage our product candidates, as monotherapies and in rational combinations, to develop new treatment options for patients in need."